Literature DB >> 19889520

In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods.

Marisa Almuzara1, Adriana Limansky, Viviana Ballerini, Laura Galanternik, Angela Famiglietti, Carlos Vay.   

Abstract

In this study, we analysed the antimicrobial susceptibility of 92 strains of Achromobacter spp. isolated from clinical samples to 18 antimicrobial agents. The disk diffusion method and Etest were compared with the agar dilution method, and the breakpoints of susceptibility and resistance for the disk diffusion method for the antimicrobials tested were determined. The most active antibiotics were piperacillin, piperacillin/tazobactam and the carbapenems. By applying the linear least-squares regression method, breakpoints could be established for antibiotics active against this genus such as imipenem, meropenem, ertapenem and trimethoprim/sulfamethoxazole (SXT). Other active antibiotics, such as piperacillin and minocycline, could be tested by the Etest method. The less active antibiotics such as gentamicin, doxycycline and tetracycline could be tested by the disk diffusion method. For the rest of the antimicrobial agents tested, breakpoints could not be established owing to the high percentage of errors and/or the poor linear regression coefficient obtained. Therefore, these antimicrobial agents should be tested by minimal inhibitory concentration determination. In summary, we recommend the following zone diameter breakpoints for resistant and susceptible, respectively: < or = 11 mm and > or = 22 mm for imipenem; < or = 13 mm and > or = 24 mm for meropenem; < or = 17 mm and > or = 24 mm for ertapenem; < or = 15 mm and > or = 21 mm for gentamicin; < or = 27 mm and > or = 28 mm for SXT; < or = 20 mm and > or = 29 mm for tetracycline; and < or = 20 mm and > or = 24 mm for doxycycline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889520     DOI: 10.1016/j.ijantimicag.2009.08.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  22 in total

1.  First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.

Authors:  Julien Bador; Lucie Amoureux; Jean-Marie Duez; Anthony Drabowicz; Eliane Siebor; Catherine Llanes; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

2.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 3.  Resemblance and divergence: the "new" members of the genus Bordetella.

Authors:  Roy Gross; Kristina Keidel; Karin Schmitt
Journal:  Med Microbiol Immunol       Date:  2010-08       Impact factor: 3.402

4.  Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Anne-Laure Michon; Raphaël Chiron; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

5.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 6.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.

Authors:  Julien Bador; Lucie Amoureux; Emmanuel Blanc; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

8.  A chromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis.

Authors:  Charlotte Marsac; Laura Berdah; Guillaume Thouvenin; Isabelle Sermet-Gaudelus; Harriet Corvol
Journal:  ERJ Open Res       Date:  2021-05-31

9.  Isolation of multiple drug-resistant enteric bacteria from feces of wild Western Lowland Gorilla (Gorilla gorilla gorilla) in Gabon.

Authors:  Pierre Philippe Mbehang Nguema; Torahiko Okubo; Sayaka Tsuchida; Shiho Fujita; Juichi Yamagiwa; Yutaka Tamura; Kazunari Ushida
Journal:  J Vet Med Sci       Date:  2015-01-30       Impact factor: 1.267

10.  Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.

Authors:  Tim Holm Jakobsen; Martin Asser Hansen; Peter Østrup Jensen; Lars Hansen; Leise Riber; April Cockburn; Mette Kolpen; Christine Rønne Hansen; Winnie Ridderberg; Steffen Eickhardt; Marlene Hansen; Peter Kerpedjiev; Morten Alhede; Klaus Qvortrup; Mette Burmølle; Claus Moser; Michael Kühl; Oana Ciofu; Michael Givskov; Søren J Sørensen; Niels Høiby; Thomas Bjarnsholt
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.